These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17222743)

  • 1. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
    Boersma E
    J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
    Cannon CP
    Clin Cardiol; 1999 Aug; 22(8 Suppl):IV30-6. PubMed ID: 10492851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
    Cole JH; Weintraub WS
    Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689
    [No Abstract]   [Full Text] [Related]  

  • 5. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
    Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
    [No Abstract]   [Full Text] [Related]  

  • 6. Economics of coronary stenting and GPIIb/IIIa blockade.
    Weintraub WS
    Eur Heart J; 2001 Aug; 22(16):1366-8. PubMed ID: 11482914
    [No Abstract]   [Full Text] [Related]  

  • 7. Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.
    Roe MT; Moliterno DJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):247-57. PubMed ID: 10373718
    [No Abstract]   [Full Text] [Related]  

  • 8. Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.
    Ben-Yehuda O
    J Am Coll Cardiol; 2006 Feb; 47(3):538-40. PubMed ID: 16458132
    [No Abstract]   [Full Text] [Related]  

  • 9. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 10. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
    Khan SS; Forrester J
    N Engl J Med; 1997 Oct; 337(17):1243; author reply 1244-5. PubMed ID: 9340527
    [No Abstract]   [Full Text] [Related]  

  • 11. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 12. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
    Exaire JE; Lincoff AM
    J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
    Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
    Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
    [No Abstract]   [Full Text] [Related]  

  • 14. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
    Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal antibodies in cardiology].
    Legrand V
    Rev Med Liege; 2009; 64(5-6):310-2. PubMed ID: 19642465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications.
    Hillegass WB; Newman AR; Raco DL
    Pharmacoeconomics; 2001 Jan; 19(1):41-55. PubMed ID: 11252545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Roe MT; Sapp SK; Lincoff AM
    Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of abciximab during coronary angioplasty].
    Philippe F; Montalescot G; Drobinski G; Thomas D
    Arch Mal Coeur Vaiss; 1997 Dec; 90(12):1645-50. PubMed ID: 9587446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
    Schrogie JJ
    Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614
    [No Abstract]   [Full Text] [Related]  

  • 20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
    Anderson KM; Bala MV; Weisman HF
    Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.